Leukemia

Chemotherapy-related Bone Loss in Children With ALL Occurs Earlier Than Previously Assumed

Chemotherapy-related Bone Loss in Children With ALL Occurs Earlier Than Previously Assumed

By

Significant bone loss in children receiving chemotherapy for acute lymphoblastic leukemia (ALL) occurs during the first month of treatment.

Dasatinib, Nilotinib, Ponatinib Increase Vascular Occlusive Events

Dasatinib, Nilotinib, Ponatinib Increase Vascular Occlusive Events

By

Dasatinib, nilotinib, and ponatinib, used in the treatment of patients with chronic myeloid leukemia (CML) increase vascular occlusive events.

Study Evaluates Gemtuzumab Ozogamicin in Older Patients With AML

Study Evaluates Gemtuzumab Ozogamicin in Older Patients With AML

By

First-line monotherapy with low-dose gemtuzumab ozogamicin significantly improved overall survival compared with best supportive care.

Blood Test Could Help Predict Acute Myeloid Leukemia Recurrence

Blood Test Could Help Predict Acute Myeloid Leukemia Recurrence

A simple blood test can identify post-chemo patients with the NPM1 gene mutation.

Molecular Signature Predicts Transition from Myelodysplastic Syndrome to Acute Myeloid Leukemia

By

Progress from myelodysplastic syndrome to AML is linked to the enzyme glycogen synthase kinase, and a molecular signature is found to predict clinical outcomes of patients with MDS.

Treatment-related Anxiety for Pediatric Patients with Acute Lymphoblastic Leukemia Examined

Treatment-related Anxiety for Pediatric Patients with Acute Lymphoblastic Leukemia Examined

By

A new study examined levels of procedure-related anxiety in children with standard-risk acute lymphoblastic leukemia (ALL).

Antibody Therapy Beneficial for Patients With Leukemia Undergoing Stem Cell Transplant

Antibody Therapy Beneficial for Patients With Leukemia Undergoing Stem Cell Transplant

Results for patients with acute leukemia that received the antibody showed lower incidence of chronic graft-versus-host disease post-transplant.

Immunotherapeutic Agent Blocks Protein-Protein Interaction That Supports Chronic Lymphocytic Leukemia Growth and Metastasis

Immunotherapeutic Agent Blocks Protein-Protein Interaction That Supports Chronic Lymphocytic Leukemia Growth and Metastasis

By

Wnt5a protein acts on a pair of tumor-surface proteins to accelerate the proliferation and spread of CLL. These effects of Wnt5a were blocked by a humanized monoclonal antibody called cirmtuzumab, according to a recent study.

Adolescents and Young Adults With Blood Cancers Experience Substantial Pyschological Morbidities

Adolescents and Young Adults With Blood Cancers Experience Substantial Pyschological Morbidities

By

Adolescents and young adults (AYAs) with hematologic malignancies experience significant psychological morbidities during treatment and early survivorship.

Vitamin D Deficiency May Be Associated With Increased Risk of Leukemia

By

People residing at higher latitudes, who are exposed to lower levels of sunlight/ultraviolet B light and have a higher prevalence of vitamin D deficiency, are at least twice as likely to develop leukemia than equatorial populations.

Survey Shows Clinician Opinions on Timing of End-of-life Discussions for Patients With Blood Cancers

By

In a survey on end-of-life (EOL) discussions, hematologic oncologists reported that these discussions with patients who have blood cancers occur too late, according to a recent report.

Predictive Panel Detects Invasive Pulmonary Aspergillosis in Patients With Leukemia

Predictive Panel Detects Invasive Pulmonary Aspergillosis in Patients With Leukemia

By

A team of researchers discovered a method for early detection of aspergillosis, a potentially deadly fungal infection, in patients whose disease or treatment involves immune system suppression.

Certain Characteristics Increase Leukemia Risk for Some Breast Cancer Survivors

By

A new analysis indicates that certain characteristics may indicate a higher risk of developing leukemia after chemotherapy and/or radiation for breast cancer survivors.

Association Is Found Between Bone Complications in Young Pediatric Patients With Leukemia and Gene Variations

By

Variations in genes involved in normal bone development are associated with an 8- to 15-fold increased risk for osteonecrosis in young patients with acute lymphoblastic leukemia (ALL).

ASH: Ibrutinib Superior to Chlorambucil for Chronic Lymphocytic Leukemia

ASH: Ibrutinib Superior to Chlorambucil for Chronic Lymphocytic Leukemia

Improvements were observed in progression-free survival, overall survival, and response rate for ibrutinib usage.

Idelalisib With Bendamustine and Rituximab Superior to Bendamustine and Rituximab alone for Relapsed/Refractory CLL

Idelalisib With Bendamustine and Rituximab Superior to Bendamustine and Rituximab alone for Relapsed/Refractory CLL

By

For patients with relapsed/refractory CLL, the addition of idelalisib to bendamustine and rituximab can prove more beneficial than the latter two drugs alone, recent study data suggest.

Pretransplant Myeloablative Regimens Confirmed Standard of Care for MDS, AML

Pretransplant Myeloablative Regimens Confirmed Standard of Care for MDS, AML

By

Results of a phase 3 randomized trial support high intensity conditioning with myeloablative regimens prior to allogeneic stem cell transplantation as standard of care for patients with acute myeloid leukemia.

Venetoclax Induces Deep Remissions in Ultra-High Risk Relapsed/Refractory CLL with 17p Deletion

Venetoclax Induces Deep Remissions in Ultra-High Risk Relapsed/Refractory CLL with 17p Deletion

By

Treatment with venetoclax monotherapy may be a viable option for some high-risk patients with relapsed/refractory chronic lymphocytic leukemia.

More Sustainable Pricing Needed for Oral Treatments for Chronic Lymphocytic Leukemia

More Sustainable Pricing Needed for Oral Treatments for Chronic Lymphocytic Leukemia

By

The high cost of for first-line oral targeted therapies for chronic lymphocytic leukemia needs to be addressed, based on model data examining CLL prevalence and patient affordability.

COG: Immunophenotypic Expression Profiles Can Help Predict Outcome in AML

COG: Immunophenotypic Expression Profiles Can Help Predict Outcome in AML

By

Immunophenotypic expression profiles can provide a tool to discriminate cohorts of young patients with acute myeloid leukemia (AML) that have a high relapse probability.

Extended Dosing of Oral Azacitidine Safe in Acute Myeloid Leukemia

Extended Dosing of Oral Azacitidine Safe in Acute Myeloid Leukemia

By

An oral formulation of azacitidine was safe and clinically active in patients with acute myeloid leukemia (AML), according to results presented at the 57th American Society of Hematology Annual Meeting.

Allogeneic SCT: A Curative Strategy for Primary Refractory AML

Allogeneic SCT: A Curative Strategy for Primary Refractory AML

By

For patients with refractory acute myeloid leukemia (AML), employment of allogeneic stem cell transplantation may be a valid treatment strategy.

Arsenic Trioxide Reduces Relapse in Standard Risk Newly Diagnosed APL

Arsenic Trioxide Reduces Relapse in Standard Risk Newly Diagnosed APL

By

Arsenic trioxide can lower relapse rates in first-line treatment of standard risk acute promyelocytic leukemia (APL), but proper administration is required.

Ponatinib Ups Overall Survival in Patients with CP-CML and T315I Mutation

Ponatinib Ups Overall Survival in Patients with CP-CML and T315I Mutation

By

For patients with chronic phase chronic myeloid leukemia (CP-CML) and the T315I mutation, ponatinib treatment may offer longer overall survival.

No Survival Benefit to Fourth Chemo Course in Younger Patients with AML

No Survival Benefit to Fourth Chemo Course in Younger Patients with AML

By

Although a fourth chemotherapy course may benefit younger patients with poor-risk acute myeloid leukemia, those with good and standard risk demonstrated little survival benefit from the additional course.

Addition of Midostaurin Significantly Improved Event-Free and Overall Survival in Some Patients With Acute Myeloid Leukemia

Addition of Midostaurin Significantly Improved Event-Free and Overall Survival in Some Patients With Acute Myeloid Leukemia

By

The addition of midostaurin, a multi-target protein kinase inhibitor, to to standard chemotherapy for AML has been associated with increased survival.

Antibiotic Prophylaxis During Induction Phase Reduces Infections in Pediatric ALL

Antibiotic Prophylaxis During Induction Phase Reduces Infections in Pediatric ALL

By

Continuous antibiotic treatment can reduce infections in young patients with acute lymphoblastic leukemia (ALL).

Fractures Higher in Non-Hispanic Patients Treated for Newly Diagnosed Pediatric ALL

Fractures Higher in Non-Hispanic Patients Treated for Newly Diagnosed Pediatric ALL

By

Non-Hispanic children undergoing treatment for newly diagnosed acute lymphoblastic leukemia reported higher rates of fractures and opportunistic infections, according to new study data.

Leukemic Mutations Create 'Therapeutic Window' for Spliceosome Modulators

Leukemic Mutations Create 'Therapeutic Window' for Spliceosome Modulators

By

Spliceosomal-mutant leukemias displayed greater sensitivity to pharmacologic modulation of splicing than their wildtype counterparts.

Addition of Rituximab Significantly Improved Treatment of Patients With B-cell Non-Hodgkin Lymphoma

Addition of Rituximab Significantly Improved Treatment of Patients With B-cell Non-Hodgkin Lymphoma

By

A new randomized study has evaluated the addition of rituximab to the pediatric-inspired GRAALL protocol for adults with acute lymphoblastic leukemia.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs